{"title":"肿瘤干细胞标志物CD133和OCT4在早期非小细胞肺癌筛查及预后评价中的联合检测","authors":"Shuhong Guan, Junkang Huangfu, Xiaoqin Zhu, Yunqi Ge, Ying Ding, Tianyu Chen, Yilei Zhang, Tingting Yang, Huimin Liu, Long Zhang, Xiyao Chen, Jun Zhou","doi":"10.2147/CMAR.S551828","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression of cancer stem cell (CSC) markers CD133 and OCT4 in early-stage non-small cell lung cancer (NSCLC), evaluate their diagnostic value in early screening, and analyze their prognostic significance.</p><p><strong>Methods: </strong>A retrospective study was conducted on 80 patients with early-stage NSCLC (stages I-IIA) and 40 healthy controls from January 2021 to December 2023. Expression levels of CD133 and OCT4 were assessed by immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR). Clinicopathological data were analyzed, and all patients were followed for 24 months to assess overall survival (OS). Diagnostic efficacy was evaluated by ROC analysis, and prognostic factors were identified by Cox regression.</p><p><strong>Results: </strong>CD133 and OCT4 were significantly upregulated in NSCLC tissues compared with adjacent normal tissues and healthy controls (P<0.001). High expression correlated with poor differentiation, larger tumor size (≥3 cm), lymph node metastasis, and stage IB-IIA (P<0.05). ROC analysis showed AUCs of 0.809 for CD133, 0.796 for OCT4, and 0.893 for their combination, with combined sensitivity of 88.7% and specificity of 82.5%. Patients with high expression of both markers had markedly reduced 2-year OS compared with low-expression cases (P<0.01). Multivariate Cox regression identified high CD133 expression (HR=2.45, 95% CI: 1.38-4.36, P=0.003), high OCT4 expression (HR=2.17, 95% CI: 1.22-3.86, P=0.007), poor differentiation (HR=1.91, P=0.021), tumor size ≥3 cm (HR=1.84, P=0.039), lymph node metastasis (HR=2.08, P=0.020), and stage IB-IIA (HR=2.22, P=0.016) as independent prognostic risk factors.</p><p><strong>Conclusion: </strong>CD133 and OCT4 are overexpressed in early-stage NSCLC and are associated with aggressive disease and poor prognosis. Combined detection provides superior diagnostic accuracy (AUC=0.893) compared to single markers and may serve as a valuable biomarker panel for early screening and risk stratification. These markers also have potential utility in guiding individualized treatment strategies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"2077-2087"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456660/pdf/","citationCount":"0","resultStr":"{\"title\":\"Combined Detection of Tumor Stem Cell Markers CD133 and OCT4 in Early Non-Small Cell Lung Cancer Screening and Prognostic Evaluation.\",\"authors\":\"Shuhong Guan, Junkang Huangfu, Xiaoqin Zhu, Yunqi Ge, Ying Ding, Tianyu Chen, Yilei Zhang, Tingting Yang, Huimin Liu, Long Zhang, Xiyao Chen, Jun Zhou\",\"doi\":\"10.2147/CMAR.S551828\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the expression of cancer stem cell (CSC) markers CD133 and OCT4 in early-stage non-small cell lung cancer (NSCLC), evaluate their diagnostic value in early screening, and analyze their prognostic significance.</p><p><strong>Methods: </strong>A retrospective study was conducted on 80 patients with early-stage NSCLC (stages I-IIA) and 40 healthy controls from January 2021 to December 2023. Expression levels of CD133 and OCT4 were assessed by immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR). Clinicopathological data were analyzed, and all patients were followed for 24 months to assess overall survival (OS). Diagnostic efficacy was evaluated by ROC analysis, and prognostic factors were identified by Cox regression.</p><p><strong>Results: </strong>CD133 and OCT4 were significantly upregulated in NSCLC tissues compared with adjacent normal tissues and healthy controls (P<0.001). High expression correlated with poor differentiation, larger tumor size (≥3 cm), lymph node metastasis, and stage IB-IIA (P<0.05). ROC analysis showed AUCs of 0.809 for CD133, 0.796 for OCT4, and 0.893 for their combination, with combined sensitivity of 88.7% and specificity of 82.5%. Patients with high expression of both markers had markedly reduced 2-year OS compared with low-expression cases (P<0.01). Multivariate Cox regression identified high CD133 expression (HR=2.45, 95% CI: 1.38-4.36, P=0.003), high OCT4 expression (HR=2.17, 95% CI: 1.22-3.86, P=0.007), poor differentiation (HR=1.91, P=0.021), tumor size ≥3 cm (HR=1.84, P=0.039), lymph node metastasis (HR=2.08, P=0.020), and stage IB-IIA (HR=2.22, P=0.016) as independent prognostic risk factors.</p><p><strong>Conclusion: </strong>CD133 and OCT4 are overexpressed in early-stage NSCLC and are associated with aggressive disease and poor prognosis. Combined detection provides superior diagnostic accuracy (AUC=0.893) compared to single markers and may serve as a valuable biomarker panel for early screening and risk stratification. These markers also have potential utility in guiding individualized treatment strategies.</p>\",\"PeriodicalId\":9479,\"journal\":{\"name\":\"Cancer Management and Research\",\"volume\":\"17 \",\"pages\":\"2077-2087\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456660/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Management and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/CMAR.S551828\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S551828","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Combined Detection of Tumor Stem Cell Markers CD133 and OCT4 in Early Non-Small Cell Lung Cancer Screening and Prognostic Evaluation.
Objective: To investigate the expression of cancer stem cell (CSC) markers CD133 and OCT4 in early-stage non-small cell lung cancer (NSCLC), evaluate their diagnostic value in early screening, and analyze their prognostic significance.
Methods: A retrospective study was conducted on 80 patients with early-stage NSCLC (stages I-IIA) and 40 healthy controls from January 2021 to December 2023. Expression levels of CD133 and OCT4 were assessed by immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR). Clinicopathological data were analyzed, and all patients were followed for 24 months to assess overall survival (OS). Diagnostic efficacy was evaluated by ROC analysis, and prognostic factors were identified by Cox regression.
Results: CD133 and OCT4 were significantly upregulated in NSCLC tissues compared with adjacent normal tissues and healthy controls (P<0.001). High expression correlated with poor differentiation, larger tumor size (≥3 cm), lymph node metastasis, and stage IB-IIA (P<0.05). ROC analysis showed AUCs of 0.809 for CD133, 0.796 for OCT4, and 0.893 for their combination, with combined sensitivity of 88.7% and specificity of 82.5%. Patients with high expression of both markers had markedly reduced 2-year OS compared with low-expression cases (P<0.01). Multivariate Cox regression identified high CD133 expression (HR=2.45, 95% CI: 1.38-4.36, P=0.003), high OCT4 expression (HR=2.17, 95% CI: 1.22-3.86, P=0.007), poor differentiation (HR=1.91, P=0.021), tumor size ≥3 cm (HR=1.84, P=0.039), lymph node metastasis (HR=2.08, P=0.020), and stage IB-IIA (HR=2.22, P=0.016) as independent prognostic risk factors.
Conclusion: CD133 and OCT4 are overexpressed in early-stage NSCLC and are associated with aggressive disease and poor prognosis. Combined detection provides superior diagnostic accuracy (AUC=0.893) compared to single markers and may serve as a valuable biomarker panel for early screening and risk stratification. These markers also have potential utility in guiding individualized treatment strategies.
期刊介绍：
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
